Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Relmada Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Relmada Therapeutics, Inc.’s stock price such as:

• Relmada Therapeutics, Inc.’s current stock price and volume
• Why Relmada Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for RLMD from analysts
• RLMD’s stock price momentum as measured by its relative strength

About Relmada Therapeutics, Inc. (RLMD)

Before we jump into Relmada Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Want to learn more about Relmada Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Relmada Therapeutics, Inc..

Relmada Therapeutics, Inc.’s Stock Price as of Market Close

As of February 19, 2026, 11:48 AM, CST, Relmada Therapeutics, Inc.’s stock price was $4.230.

Relmada Therapeutics, Inc. is up 3.68% from its previous closing price of $4.080.

During the last market session, Relmada Therapeutics, Inc.’s stock traded between $4.033 and $4.300. Currently, there are approximately 33.19 million shares outstanding for Relmada Therapeutics, Inc..

Relmada Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Relmada Therapeutics, Inc. Stock Price History

Relmada Therapeutics, Inc.’s (RLMD) price is currently up 19.16% so far this month.

During the month of February, Relmada Therapeutics, Inc.’s stock price has reached a high of $4.350 and a low of $3.221.

Over the last year, Relmada Therapeutics, Inc. has hit prices as high as $5.120 and as low as $0.240. Year to date, Relmada Therapeutics, Inc.’s stock is down 12.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Relmada Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 18, 2026, there were analysts who downgraded Relmada Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Relmada Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Relmada Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Relmada Therapeutics, Inc. (RLMD) by visiting AAII Stock Evaluator.

Relative Price Strength of Relmada Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 18, 2026, Relmada Therapeutics, Inc. has a weighted four-quarter relative price strength of 117.00%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Relmada Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Relmada Therapeutics, Inc. Stock Price: Bottom Line

As of February 19, 2026, Relmada Therapeutics, Inc.’s stock price is $4.230, which is up 3.68% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Relmada Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.